CRNX vs. MRNA, ASND, VTRS, QGEN, ROIV, RVMD, BPMC, BBIO, ELAN, and VRNA
Should you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry.
Crinetics Pharmaceuticals vs.
Moderna (NASDAQ:MRNA) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
In the previous week, Moderna had 27 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 37 mentions for Moderna and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.43 beat Moderna's score of 0.57 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.
Moderna presently has a consensus target price of $53.58, suggesting a potential upside of 100.22%. Crinetics Pharmaceuticals has a consensus target price of $74.56, suggesting a potential upside of 152.73%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Moderna.
Crinetics Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -110.04%. Moderna's return on equity of -28.74% beat Crinetics Pharmaceuticals' return on equity.
75.3% of Moderna shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 11.0% of Moderna shares are held by insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Moderna has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.
Crinetics Pharmaceuticals has lower revenue, but higher earnings than Moderna. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Moderna received 57 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 69.43% of users gave Crinetics Pharmaceuticals an outperform vote while only 53.20% of users gave Moderna an outperform vote.
Summary
Crinetics Pharmaceuticals beats Moderna on 10 of the 19 factors compared between the two stocks.
Get Crinetics Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crinetics Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CRNX) was last updated on 5/28/2025 by MarketBeat.com Staff
